menu
    • menu
    [{"orgOrder":0,"company":"Guy's and St Thomas' NHS Foundation Trust","sponsor":"ViiV Healthcare | Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Maraviroc","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Guy's and St Thomas' NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Guy's and St Thomas' NHS Foundation Trust \/ ViiV Healthcare | Gilead Sciences","highestDevelopmentStatusID":"11","companyTruncated":"Guy's and St Thomas' NHS Foundation Trust \/ ViiV Healthcare | Gilead Sciences"},{"orgOrder":0,"company":"HealthBioAI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Maraviroc","moa":"||C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"HealthBioAI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"HealthBioAI \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"HealthBioAI \/ Inapplicable"},{"orgOrder":0,"company":"HealthBio, Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Maraviroc","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HealthBio, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HealthBio, Inc. \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"HealthBio, Inc. \/ Inapplicable"},{"orgOrder":0,"company":"Hospital Universitario Infanta Leonor","sponsor":"Hospital Clinic of Barcelona | ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Maraviroc","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Hospital Universitario Infanta Leonor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hospital Universitario Infanta Leonor \/ Hospital Clinic of Barcelona | ViiV Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Hospital Universitario Infanta Leonor \/ Hospital Clinic of Barcelona | ViiV Healthcare"},{"orgOrder":0,"company":"University of Calgary","sponsor":"University Health Network, Toronto | University of California, Los Angeles | Sunnybrook Health Sciences Centre | University of British Columbia | Memorial University of Newfoundland | Dalhousie University | Parkwood Hospital, London, Ontario | Riverview H","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Maraviroc","moa":"C-C chemokine receptor type 5","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of Calgary","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Calgary \/ University Health Network, Toronto | University of California, Los Angeles | Sunnybrook Health Sciences Centre | University of British Columbia | Memorial University of Newfoundland | Dalhousie University | Parkwood Hospital, London, Ontario | Riverview H","highestDevelopmentStatusID":"8","companyTruncated":"University of Calgary \/ University Health Network, Toronto | University of California, Los Angeles | Sunnybrook Health Sciences Centre | University of British Columbia | Memorial University of Newfoundland | Dalhousie University | Parkwood Hospital, London, Ontario | Riverview H"},{"orgOrder":0,"company":"IncellDx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Maraviroc","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IncellDx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IncellDx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"IncellDx \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Maraviroc

    Menu

    Maraviroc

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            HealthBio, Inc.

                            Country arrow
                            Coatings Trends
                            Not Confirmed

                            HealthBio, Inc.

                            Country arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maraviroc

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Investigating Measurable PRO Acuity Trial (IMPACT) is a Multi-Center Randomized, Double-Blind, Placebo-Control...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 15, 2025

                            Lead Product(s) : Maraviroc

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            HealthBioAI

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            HealthBioAI

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maraviroc,Atorvastatin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            HealthBioAI Receives FDA Acceptance for Long COVID Trial with Selzentry® and Lipitor

                            Details : Selzentry (maraviroc) is a CCR5 co-receptor antagonist, in combination with Lipitor (atorvastatin) is being evaluated for the treatment of Long COVID/Post Acute Sequelae of COVID.

                            Product Name : Selzentry

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 15, 2024

                            Lead Product(s) : Maraviroc,Atorvastatin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Guy's and St Thomas' NHS Foundation Trust

                            Country arrow
                            Coatings Trends
                            Not Confirmed

                            Guy's and St Thomas' NHS Foundation Trust

                            Country arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maraviroc

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : ViiV Healthcare | Gilead Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Role of Home Packs of HIV PEPSE in High Risk Individuals

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 16, 2021

                            Lead Product(s) : Maraviroc

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : ViiV Healthcare | Gilead Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            University of Calgary

                            Country arrow
                            Coatings Trends
                            Not Confirmed

                            University of Calgary

                            Country arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maraviroc

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : University Health Network, Toronto | University of California, Los Angeles | Sunnybrook Health Sciences Centre | University of British Columbia | Memorial University of Newfoundland | Dalhousie University | Parkwood Hospital, London, Ontario | Riverview H

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After Stroke

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 09, 2021

                            Lead Product(s) : Maraviroc

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : University Health Network, Toronto | University of California, Los Angeles | Sunnybrook Health Sciences Centre | University of British Columbia | Memorial University of Newfoundland | Dalhousie University | Parkwood Hospital, London, Ontario | Riverview H

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            IncellDx

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed

                            IncellDx

                            U.S.A arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maraviroc

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            IncellDx to Study Maraviroc in a COVID-19 Phase 2 Clinical Trial

                            Details : The trial "Open-Label Study of Maraviroc in Hospitalized Individuals Diagnosed With SARS-CoV-2" seeks to establish whether a one week treatment with Maraviroc, used at its approved dosage for HIV, is safe and tolerable in patients with SARS-CoV-2.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 20, 2020

                            Lead Product(s) : Maraviroc

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Hospital Universitario Infanta Leonor

                            Country arrow
                            Coatings Trends
                            Not Confirmed

                            Hospital Universitario Infanta Leonor

                            Country arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maraviroc

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Hospital Clinic of Barcelona | ViiV Healthcare

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 22, 2020

                            Lead Product(s) : Maraviroc

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Hospital Clinic of Barcelona | ViiV Healthcare

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            University College, London

                            Country arrow
                            Coatings Trends
                            Not Confirmed

                            University College, London

                            Country arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maraviroc

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II/ Phase III

                            Sponsor : Medical Research Council | ViiV Healthcare | Royal Free Hospital NHS FT

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adding MAraViroc &/or METformin for Hepatic Steatosis in People Living With HIV

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 26, 2017

                            Lead Product(s) : Maraviroc

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Medical Research Council | ViiV Healthcare | Royal Free Hospital NHS FT

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            German Center for Diabetes Research

                            Country arrow
                            Coatings Trends
                            Not Confirmed

                            German Center for Diabetes Research

                            Country arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maraviroc

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : FAPESP | Conselho Nacional de Desenvolvimento Científico e Tecnológico | ViiV Healthcare

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Steriliz...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 11, 2016

                            Lead Product(s) : Maraviroc

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : FAPESP | Conselho Nacional de Desenvolvimento Científico e Tecnológico | ViiV Healthcare

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Southern California Institute for Research and Education

                            Country arrow
                            Coatings Trends
                            Not Confirmed

                            Southern California Institute for Research and Education

                            Country arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maraviroc

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adding Maraviroc to the HAART Regimen of Well Controlled HIV-infected Patients

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 14, 2016

                            Lead Product(s) : Maraviroc

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Pfizer Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            University of Maryland, Baltimore

                            Country arrow
                            Coatings Trends
                            Not Confirmed

                            University of Maryland, Baltimore

                            Country arrow
                            Coatings Trends
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Maraviroc

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : ViiV Healthcare

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Maraviroc Efficacy for Hepatitis C

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 29, 2016

                            Lead Product(s) : Maraviroc

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : ViiV Healthcare

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth